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Susan G. Amara 
The Vellum Institute for Advanced Biomedical Research, Oregon Health Sciences University, Portland, Oregon 97201 
Reuptake plays an important role in regulating synaptic and 
extracellular concentrations of glutamate. Three glutamate 
transporters expressed in human motor cortex, termed 
EAATl , EAATP, and EAAT3 (for excitatory amino acid trans- 
porter), have been characterized by their molecular cloning 
and functional expression. Each EAAT subtype mRNA was 
found in all human brain regions analyzed. The most prom- 
inent regional variation in message content was in cerebel- 
lum where EAATl expression predominated. EAATl and 
EAAT3 mRNAs were also expressed in various non-nervous 
tissues, whereas expression of EAATS was largely restricted 
to brain. The kinetic parameters and pharmacological char- 
acteristics of transport mediated by each EAAT subtype 
were determined in transfected mammalian cells by radio- 
label uptake and in microinjected oocytes by voltage-clamp 
measurements. The affinities of the EAAT subtypes for L-glu- 
tamate were similar, with K, determinations varying from 48 
to 97 AM in the mammalian cell assay and from 18 to 28 NM 
in oocytes. Glutamate uptake inhibitors were used to com- 
pare the pharmacologies of the EAAT subtypes. The EAAT2 
subtype was distinguishable from the EAATl /EAAT3 sub- 
types by the potency of several inhibitors, but most notably 
by sensitivity to kainic acid (KA) and dihydrokainic acid (DHK). 
KA and DHK potently inhibited EAATP transport, but did not 
significantly affect transport by EAATl /EAAT3. Using volt- 
age-clamp measurements, most inhibitors were found to be 
substrates that elicited transport currents. In contrast, KA 
and DHK did not evoke currents and they were found to block 
EAATP-mediated transport competitively. This selective in- 
teraction with the EAATP subtype could be a significant fac- 
tor in KA neurotoxicity. These studies provide a foundation 
for understanding the role of glutamate transporters in hu- 
man excitatory neurotransmission and in neuropathology. 
[Key words: glutamate transporter, uptake, amino acids, 
human, molecular cloning, inhibitor, pharmacology, kainate, 
neurotoxicity] 
Uptake of the acidic amino acids glutamate and aspartate from 
the extracellular environment is mediated by sodium-dependent 
transport systems of high affinity that are found in both the 
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peripheral tissues (Christensen, 1990) and in the nervous system 
(Kanner and Schuldiner, 1987; Nicholls and Attwell, 1990). 
Transport serves a special function in the brain by mediating 
the reuptake of glutamate released at excitatory synapses. Glu- 
tamate can be reaccumulated from the synaptic cleft by the 
presynaptic nerve terminal (Eliasof and Werblin, 1993) or by 
glial uptake of transmitter diffusing from the cleft (Nicholls and 
Attwell, 1990; Schwartz and Tachibana, 1990; Barbour et al., 
199 1). The activities of neuronal and glial transporters influence 
the temporal and spatial dynamics of the chemical signal in 
other neurotransmitter systems (Hille, 1992; Bruns et al., 1993; 
Isaacson et al., 1993), but such effects have not yet been dem- 
onstrated at glutamatergic synapses (Hestrin et al., 1990; Sar- 
antis et al., 1993). 
Glutamate is a potent neurotoxin and transporter-mediated 
uptake serves to maintain extracellular glutamate concentra- 
tions below toxic levels. Just as the neurotoxic potency of glu- 
tamate is diminished by uptake (Choi et al., 1987; Rosenberg 
et al., 1992) the neurotoxicity of other excitatory amino acids 
may also be influenced by the nature of their interaction with 
glutamate transporters The pharmacology of glutamate trans- 
porters have been extensively investigated (Balcar and Johnston, 
1972; Ferkany and Coyle, 1986; Fletcher and Johnston, 1991; 
Robinson et al., 199 1; Rauen et al., 1992; Robinson et al., 1993) 
and exhibits a considerable degree of overlap with the phar- 
macology ofglutamate receptors (Chamberlin and Bridges, 1993). 
Thus, many of the agents that inhibit glutamate uptake are 
structural analogs ofexcitatory amino acids that act as glutamate 
receptor agonists, and whether the compound is a transporter 
substrate can be an important determinant of its neurotoxicity. 
The neurotoxic potency of kainic acid (KA), for example, may 
be enhanced because it is not taken up (Johnston et al., 1979). 
Regional differences in the potencies of various glutamate 
uptake inhibitors have suggested the existence of multiple glu- 
tamate transporter subtypes (Ferkany and Coyle, 1986; Fletcher 
and Johnston, 199 1; Robinson et al., 199 1; Rauen et al., 1992; 
Robinson et al., 1993) but a subtype pharmacology has been 
difficult to establish because of the complex nature of uptake 
systems in the brain slice, synaptosomes, or other membrane 
preparations used. An essential step toward understanding the 
contribution of uptake to the toxicity of excitatory amino acids 
is the determination of the properties of each transporter sub- 
type. 
A gene family that mediates the cellular uptake of acidic and 
neutral amino acids in mammals has recently been defined by 
molecular cloning (for reviews, see Amara and Arriza, 1993; 
Kanner, 1993; Kanai et al., 1993). Three subtypes of high-af- 
finity glutamate transporters were cloned independently (Kanai 
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and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Ta- 
naka, 1993) and sequence comparisons revealed extensive 
regions of amino acid sequence conservation. Particularly strik- 
ing was the conservation of an amino acid sequence AA(I/ 
V)FIAQ found in the mammalian glutamate transporters but 
also in prokaryotic glutamate and dicarboxylate carriers. We 
have utilized degenerate oligonucleotides based upon this se- 
quence conservation to isolate related transporter cDNAs from 
human brain. Recently, we reported the cloning and functional 
characterization of a neutral amino acid transport system that 
is also a member of the glutamate transporter gene family de- 
fined by the AA(I/V)FIAQ structural motif (Arriza et al., 1993). 
This same approach has led to the cloning of three excitatory 
amino acid transporters, EAATl, EAAT2, and EAAT3, which 
are similar to the transporters previously isolated from rat and 
rabbit. Here, we report the st-ructure, distribution, functional 
expression, and pharmacology of these human EAAT subtypes. 
Materials and Methods 
The PCR-generated coding sequences were subcloned into the ex- 
pression plasmid pCMV5 (Andersson et al., 1989) to generate constructs 
(termed pCMV-EAATI, etc.) for functional analyses in transfected 
mammalian COS-7 cells. EAAT subtype coding sequences were also 
subcloned into pOTV for expression in Xenopus laevis oocytes. pOTV 
is an oocyte transcription vector utilizing the T7 polymerase promoter 
for in vitro transcription of RNA. The coding sequences were inserted 
between Xenopus fl-globin 5’- and 3’-untranslated regions derived from 
pSP64T (Krieg and Melton, 1984) to enhance expression levels in oo- 
cytes. The resulting expression plasmids are termed pOTV-EAAT 1, etc. 
Northern blot analysis. Human brain region RNAs were prepared 
(Chomczynski and Sacchi, 1987) from tissue provided by the Oregon 
Brain Repository. RNAs were size fractionated on denaturing formal- 
dehyde gels and transferred to nylon membrane. The human peripheral 
tissue Northern blot was obtained from Clontech Laboratories. The 
coding sequences of EAATl, EAAT2, and EAAT3 were excised and 
radiolabeled with &*P-dCTP (New England Nuclear) by the random 
priming method (Boehringer Mannheim). Filters were hybridized over- 
night ai 42°C with cDNA probe ( lo6 cpm/ml) in 5 x SSPE, 50% for- 
mamide, 7.5 x Denhardt’s solution, 2% SDS, and 100 mg/ml of de- 
natured salmon sperm DNA. Autoradiography was performed after two 
30 min room temperature washes in 2 x SSPE, 1 .O% SDS, and two 20 
min washes at 50°C in 0.1 x SSPE. 0.1% SDS. 
cDNA cloning, sequenceanalyses, andplasmid constructions. A synthetic 
oligonucleotide complementary to a portion of GLASTl (Storck et al., 
1992; residues 395-l 15, ATINMDGTALYEALAAIFIAQ) was syn- 
thesized as a hybridization probe. This oligonucleotide sequence 15’ 
CTG (A/G)GC (A/G)AT GAA (A/G)AT GGC AGC CAG GGC (C/ 
T)TC ATA CAG GGC TGT GCC (A/G)TC CAT GTT (A/G)AT GGT 
(A/G)GC 3’1 is 128fold degenerate and utilizes human codon prefer- 
ences. Human motor cortex RNA was isolated by the method of Chom- 
czynski and Sacchi (1987) and polyA+ enriched by oligo(dT)-cellulose 
chromatography. Mixed oligo(dT)-primed and random-primed cDNA 
was synthesized from this RNA using the Superscript Choice System 
(Bethesda Research Labs, Gaithersburg, MD) and ligated into XZAPII 
(Stratagene, La Jolla, CA) to obtain a human cortex cDNA library 
(termed XZAP-hMC) with a complexity of 1 x 106 independent clones 
and an average insert size of - 2 kilobases (kb). XZAP-hMC was screened 
with 32P-labeled oligonucleotide using the following conditions for hy- 
bridization and wash: 1 x lo6 cpm/ml in 0.5 M Na,HPO,, pH 7.15, 
7% SDS for hybridization at 50°C and wash at 60°C in 2 x SSPE (20 x 
SSPE = 3 M NaCl, 0.2 M NaH,PO,, 0.02 M Na,EDTA, pH 7.4) and 1% 
SDS. Plasmids were obtained from purified plaques by in vivo excision 
(Stratagene, La Jolla, CA) and sequenced on both strands using double- 
stranded template, synthetic oligonucleotide primers (Oligos Etc.), 35S- 
dATP (New England Nuclear-Du Pont, Natick, MA), and Sequenase 
2.0 (United States Biochemical Corp., Cleveland, OH). Sequence data 
analysis was performed using MACVECTOR (IBI, New Haven, CT). The 
plasmids termed pEAAT 1, pEAAT2, and pEAAT contained cDNA 
inserts 4.1 kilobase pairs (kbp), 2.5 kbp, and 3.4 kbp, respectively. 
pEAAT and pEAAT contained in-frame termination codons at the 
5’ end of their open reading frames and the nucleotide sequences sur- 
rounding the first downstream methionine codon conform to consensus 
translation initiation sites. No in-frame termination codons were found 
in the 15 nucleotides upstream of the proposed initiator methionine of 
pEAAT3, but this sequence also conforms to the consensus initiation 
sequence and is similar to that reported for the rabbit transporter EAACI 
(Kanai and Hediger, 1992). 
Cell transfections and transport &rays. COS-7 cells were maintained 
in DMEM with 10% fetal calf serum at 5% CO,. Each EAAT subtype 
was expressed independently by DEAE dextran-mediated transfection 
of COS-7 cells with the appropriate expression plasmid (for example, 
pCMV-EAATl). Transfection of pCMV-5 was used to control for the 
level of endogenous uptake of radiolabeled L-glutamate (or D-aspartate) 
in each experimental condition. Subconfluent COS-7 cells were plated 
at a density of - 100,000 cells per well in 12-well tissue culture plates 
and transfected the following day with 0.5 pg of plasmid DNA per well 
essentially as described (Lopeta et al., 1984). Two days posttransfection, 
the cells are washed three times with 0.5 ml of room temperature D-PBS 
(2.7 mM KCl, 1.2 mM KH,PO,, 138 mM NaCl, 8.1 mM Na2HP04, pH 
- 7.4) over a period of 10 min prior to the uptake assays. 
Uptake of radiolabeled substrate or substrate plus inhibitor was as- 
sessed at room temperature in 0.5 ml of D-PBS. It was determined that 
with a substrate concentration of 1 mM the uptake rate was linear for 
at least 20 min. Routinely, assays were terminated after 10 min. To 
terminate uptake, cells were washed three times with ice cold PBS and 
solubilized in 0.5 ml of 0.1% SDS prior to scintillation counting in 5 
ml of ScintiVerse (Fisher Scientific). All assays contained 100 nM 3H- 
r+lutamate or 3H-D-aspartate diluted as necessary with cold substrate. 
Affinity constant (K,,) determinations measured uptake at 12 different 
substrate concentrations, while inhibitor constant (K,) measurements 
contained 1 PM glutamate and 12 different inhibitor concentrations. All 
points were assayed in triplicate. Data was analyzed using KALEIDA- 
GRAPH (Synergy Software, Reading, PA) for a least-squares fit to the 
Michaelis-Menten equation and an Eadie-Hofstee transformation. Cal- 
culated I’,,,, values (in pmol/well/min) varied in independent experi- 
ments from 5 1 to 5 13 for EAATl, 111 to 894 for EAAT2, and 152 to 
624 for EAAT3. Inhibition data were fitted to the Michaelis-Menten 
equation to determine the 100% of control value and the IC,,. Since 
the K, calculated using the method of Cheng and Prusoff (1973) does 
not differ significantly from the determined IC,,, these values are pre- 
sented as K, values. All values provided are the mean -+ SEM of at least 
three determinations. 
The coding sequences of each EAAT subtype were isolated from Pharmacological agents. Dihydrokainate, kainate, m-threo-&hy- 
cDNAs by the polymerase chain reaction (PCR). Thirty cycles of de- droxyaspartic acid, L-cysteine sulfinic acid, N-methyl-D-aspartate, L-ser- 
naturation (1 min, 94”C), annealing (1 min, 5S°C), and extension (2 min, ine-U-sulfate, t-aspartate-@-hydroxymate, @-glutamic acid, L-a-ami- 
72°C) were performed in 100 bl reactions that contained oligonucleotide noadipic acid, L- and D-glutamate, L- and D-aspartic acid, and t-cysteine 
primers at 1 PM each, 10 ng of plasmid cDNA template, 300 PM each were obtained from Sigma. Quisqualate, trans-(dicarboxyl)-2,4-meth- 
deoxynucleotide, Vent polymerase and reaction buffer (New England anoglutamic acid, cis-(dicarboxyl)-2,4-methanoglutamic acid, (f&p- 
Biolabs). Unique Ranking restriction sites (Asp7 18 and Xbal for EAATl chlorophenylglutamic acid, and S-sulfo-L-cysteine were from Tocris 
and EAAT2, Asp7 18 and BamH 1 for EAAT3) were incorporated into Neuramin (Bristol, UK). L-Trunk-pyrrolidine-2,4-dicarboxylic acid and 
the oliaonucleotide mimers. Primer seouences (5’ to 3’) were CGCG (a-&oxalyl-a,&diaminopropionic acid were from Research Biochem- 
GGTACC AAT ATG ACT AAA AGC AAT G and CGCG TCTAGA 
CTA CAT CTT GGT TTC ACT G for EAAT 1, CGCG GGTACC ACC 
ATG GCA TCT ACG GAA G and CGCG TCTAGA TTA TTT CTC 
ACG TTT CCA AG for EAATZ, CGCG GGTACC GCC ATG GGG 
AAA CCG GCG and CGCG GGATCC CTA GAA CTG TGA GGT 
CTG for EAAT3. Digestion of the reaction products with the appro- 
priate restriction enzymes allowed each coding sequence to be subcloned 
into expression plasmids. 
icals Inc. (Nat&k, MA). NIacetyl-L-aspartyl-L-glutamate was from Bach- 
em Bioscience (Philadelphia, PA). JH-L-glutamate (19.2 Ci/mmol), 3H- 
D-aspartate (2 1 Ci/mmol), and 3H-kainate (58 Ci/mmol) were obtained 
from New England Nuclear-Du Pont (Natick, MA). 
Expression of EAAT subtypes in oocytes. Synthetic RNA was tran- 
scribed in vitro from pOTV-EAAT 1, pOTV-EAATZ, or pOTV-EAAT3 
as described (Arriza et al., 1993) and injected into defolliculated stage 
V-VI Xenopus oocytes. Two to seven days following injection, transport 
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Figure 1. Alignment of the amino acid sequences of the human excitatory amino acid transporters EAATl , EAAT2, and EAAT3. The amino 
acid sequences deduced from cDNA nucleotide sequences are depicted. Gaps (dots) have been introduced to facilitate this alignment. Sequence 
identities are indicated by using white on black lettering at positions where at least two of the three aligned sequences predict identical amino acid 
residues. Bars are drawn over nine regions of extensive sequence hydrophobicity that may correspond to transmembrane or membrane-associated 
structures. Potential sites of N-linked glycosylation (N-X-S/T) are indicated by circling the relevant asparagine (N) residues. The nucleotide sequences 
of EAATl, EAAT2, and EAAT3 may be obtained from the GenBank database under accession numbers UO3504, UO3505, and UO3506, 
respectively. 
was measured by two-electrode voltage-clamp recording using a Dagan 
TEV-200 clamp amplifier with an Axon Instruments TL- 1 A/D inter- 
face. Oocytes were voltage clamped at -60 mV and continuously su- 
perfused with ND-96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCP, 
1 mM MgCl,, and 5 mM HEPES pH 7.5). For transport measurements, 
this buffer solution was changed to one containing the indicated con- 
centration of substrate. Current (Z) as a function of substrate concen- 
tration ([SJ) was fitted by least squares to Z = I,,,,. . [Sj/(K, + [S]) where 
I,,,,, is the maximal current and K,, is the Michaelis transport constant. 
Values of K,, and I,,,,, are expressed as mean + SEM and were deter- 
mined by fitting data from individual oocytes. The I,,,,, values for trans- 
porter substrates are expressed as the I,,,,, relative to that determined 
for L-glutamate in the same cells. The antagonism of EAAT2 transport 
by kainic acid and dihydrokainic acid was evaluated using Schild anal- 
ysis (Arunlakshana and Schild, 1959). 
Results 
Molecular cloning of EAA TI, EAA T2, and EAA T3 from 
human cortex 
The three human glutamate transporters characterized here were 
isolated as cDNAs from a human motor cortex library using a 
degenerate oligonucleotide probe (see Materials and Methods). 
The plasmids pEAAT 1, pEAAT2, and pEAAT contained dis- 
tinct cDNA sequences with large open reading frames identified 
by nucleotide sequence analysis. The predicted amino acid se- 
quences of the encoded proteins, termed EAATl, EAAT2, and 
EAAT3, are 542, 574, and 525 amino acids in length, respec- 
tively, as shown in Figure 1. The theoretical molecular weights 
of EAATl, EAAT2, and EAAT3 are 59.5, 62.1 and 57.2 kDa. 
On the basis of nucleic acid and amino acid sequence homology, 
EAAT 1, EAAT2, and EAAT3 could correspond to glutamate 
transporters previously isolated from other species. EAAT 1 has 
96% amino acid sequence identity with the rat GLASTl se- 
quence (Storck et al., 1992). Similarly, EAAT2 has 95% identity 
with the corrected sequence (Kanner, 1993) of rat GLT 1 (Pines 
et al., 1992) and EAAT3 has 92% identity with the rabbit 
sequence termed EAAC 1 (Kanai and Hediger, 1992). However, 
recent evidence suggests the existence of at least two additional 
human glutamate transporter subtypes, one of which is strik- 
ingly similar to both EAATl and GLASTl (W. Fairman, un- 
published data). Thus it is possible that EAATI is a novel sub- 
type rather than the human homolog of GLASTI. 
Alignment of the EAAT protein amino acid sequences illus- 
trates the extensive conservation of both primary sequence and 
other structural features within this gene family. The N- and 
C-termini differ in sequence and in length, but 70% of the po- 
sitions in the region where these three protein sequences overlap 
are identical in at least two of the three sequences. Accordingly, 
the hydropathy profiles of the EAAT subtypes are very similar 
when algorithms designed to identify transmembrane helices 
are utilized (Engelman et al., 1986), and nine major regions of 
amino acid sequence hydrophobicity have been indicated in 
Figure 1. However, predictions of the secondary structure of 
these regions are often more consistent with ,&sheets than a-hel- 
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Figure 2. Expression of EAAT subtype mRNAs in human tissues. A, Northern blot analyses of RNAs prepared from dissected brain regions with 
radiolabeled coding sequences foreither EAATl, EAATZ, or EAAT3. Each lane contains approximately 20 pg of total RNA, and the autoradiograms 
were exposed 12 hr for EAATl and EAAT2, and 24 hr for EAAT3. The estimated size of each mRNA in kilobases (kb) is indicated. Hybridization 
of a human P-actin cDNA probe to a parallel blot suggests hat the motor cortex lane contains more RNA than the other lanes. B, A single blot 
containing approximately 2 pg of polyA+ RNA from each indicated human tissue was successively hybridized with each EAAT cDNA probe. The 
same filter was also reprobed with a human P-actin cDNA to normalize for relative mRNA loading. @-Actin mRNA is approximately 2.0 kb in 
length, but heart and skeletal muscle contain an abundant 1.7 kb actin mRNA species that also hybridizes. 
ices, and the actual number of transmembrane or membrane- 
associated domains has not been established. The amino ter- 
minus is likely to be intracellular since there is no signal peptide 
sequence, and the conservation in each subtype of potential 
N-linked glycosylation sites between the third and fourth hy- 
drophobic regions (Fig. 1) suggests that this domain is extra- 
cellular. 
RNA distribution by Northern blot analyses 
Northern blot analysis of RNAs prepared from a variety of 
human tissues was used to determine the distribution of EAAT 
subtype mRNAs. The subtype mRNA content was compared 
in five human brain regions (Fig. 2A). Hybridization with an 
EAATl probe revealed a -4.2 kb mRNA relatively abundant 
in all regions examined, but significantly enriched in the cere- 
bellum. In contrast, EAAT2 mRNA (- 10.0 kb) was poorly 
represented in the cerebellar preparation, but was very abundant 
in other brain regions. In contrast to the multiple RNA species 
reported for EAACl (Kanai and Hediger, 1992), a single hy- 
bridizing band (-3.8 kb) was seen with the EAAT3 cDNA 
probe, and this band was found at low levels and in a pattern 
similar to that observed for the constitutively expressed ,&actin 
mRNA. Although the rabbit transporter EAACl has been re- 
ported to exhibit a neuronal pattern of expression (Kanai and 
Hediger, 1992), EAAT3 mRNA content did not differ signifi- 
cantly between regions such as the hippocampus that have a 
high density ofglutamatergic neurons, and a region like the basal 
ganglia that has few glutamatergic neurons (Fig. 2A). 
The expression of EAAT subtypes in various human periph- 
eral tissues was also examined (Fig. 2B). EAATl RNA was 
nearly as abundant in heart and skeletal muscle as in brain, and 
was also detectable in placenta and lung. This result contrasts 
with the reported brain-specific distribution of the structurally 
similar rat GLASTl (Storck et al., 1992). The distribution of 
EAAT2 mRNA, like GLTl (Pines et al., 1992), was rather re- 
stricted; aside from brain, detectable levels were found in only 
one other tissue examined, the placenta. EAAT3 RNA was most 
abundant in kidney with lower levels in brain, lung, and pla- 
centa, and message detectable in liver, muscle, and heart. The 
low level of EAAT3 expression in lung and heart also differs 
somewhat from the reported distribution of EAACl (Kanai and 
Hediger, 1992). 
Functional expression in mammalian cells 
Functional characterization of the EAAT subtypes was per- 
formed by transient expression in mammalian cells. The coding 
sequences of each subtype cDNA were inserted into the COS 
cell expression plasmid pCMV5, and the resulting constructs, 
pCMV-EAAT 1, pCMV-EAAT2, and pCMV-EAAT3, were 
transfected into COS-7 cells. This expression system provided 
levels of radiolabeled substrate uptake significantly ( 1 O-l OO- 
fold) greater than that of endogenous COS-7 cell uptake. En- 
dogenous uptake was measured in parallel control experiments 
in which COS-7 cells were transfected with the parental pCMV5 
plasmid, and subtracted from each data point. Each assay point 
was performed in triplicate and each experiment was performed 
at least three times. 
The kinetics of the cellular uptake of the glutamate transporter 
substrates L-glutamate and D-aspartate were examined for 
EAATl, EAAT2, and EAAT3 (Fig. 3). Uptake (in pmol/well/ 
min) as a function of substrate concentration was fitted by least- 
squares to the Michaelis-Menten equation, and the half-maxi- 
mal transport constant (K,) was determined using the Eadie- 
Hofstee transformation (insets, Fig. 3). The K,,, values of EAATl, 
EAAT2, and EAAT3 for uptake of L-glutamate were 48 + 10, 
97 + 4, and 62 f 8 PM, respectively (Fig. 3A,C,E). Uptake of 
the nonmetabolized amino acid D-aspartate yielded K, values 
of 60 f 12, 54 + 9, and 47 _+ 9 PM for EAATl, EAAT2, and 
EAAT3, respectively (Fig. 3B,D,F). Subtype I’,,,, determina- 
tions could not be directly compared in this assay system be- 
cause of the dependence on efficiency of transfection and other 
factors related to the level of expression. The I’,,,, of a single 
subtype was observed to vary as much as IO-fold between ex- 
periments, and without specific antibodies or high affinity li- 
gands it is not possible to compare the level of expression of a 
A. EAATI 
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particular subtype. There was no evidence, however, that the 
transport K,,, was affected by expression level. 
Pharmacological characterization of the EAA T subtypes 
The pharmacological properties of the human glutamate trans- 
porter subtypes were characterized in assays similar to those 
described above, but with a fixed concentration of radiolabeled 
glutamate (1 PM) and varying drug concentrations. Candidate 
drugs were initially tested at three concentrations (3 PM, 100 
PM, 3 mM) to determine their potency and specificity. This three- 
point screen was subsequently found to provide approximate 
K, values generally consistent with those determined by more 
complete (6-12 point) assays. The following compounds were 
only characterized by three-point assays. HgCl, was a potent 
inhibitor of EAATI, EAAT2, and EAAT3 (K, = 31 PM, 99 PM, 
Figure 3. Excitatory amino acid up- 
take by EAAT subtypes expressed in 
transfected COS-7 cells. The kinetic 
properties of the cellular uptake of )H- 
L-glutamate (A, C, E) or 3H-o-aspartate 
(B, D, E) as mediated by EAATl (A, 
B), EAATZ (C, D), or EAAT3 (E, F) 
were assessed by the transient expres- 
sion of these transporters in COS-7 cells. 
Uptake velocity (in pmol/well/min) was 
measured using 100 nM of radiolabeled 
amino acid and increasing concentra- 
tions of unlabeled amino acid. The data 
presented are the mean of triplicate de- 
terminations from single representative 
experiments, and individual determi- 
nations for each point did not vary from 
the mean by > 20%. K,” values were ob- 
tained from the Eadie-Hofstee plots (in- 
sets), and the values presented are the 
mean * SEM of at least three indepen- 
dent experiments. 
and 62 FM, respectively; n = 2). Trans-(dicarboxyl)-2,4-meth- 
anoglutamic acid, an uptake inhibitor reported to be relatively 
inactive at glutamate receptors (Fletcher et al., 199 l), provided 
K, estimates of 120 f 21, 660 f 153, and 244 + 94 PM (n = 
3) for EAATl, EAAT2, and EAAT3. Its stereoisomer [cis-(di- 
carboxyl)-2,4-methanoglutamic acid], a NMDA receptor ago- 
nist (Lanthom et al., 1990) did not inhibit uptake. Compounds 
with determined K, values of 2 1 mM in this assay system were 
defined as inactive. Other inactive compounds were NMDA, 
quisqualate, (S)-P-oxalyl-cY,p-diaminopropionic acid (ODAP); 
(*)/3-p-chlorophenylglutamic acid, N-acetyl aspartylglutamate 
(NAAG), L-cysteine, and S-sulfo-L-cysteine. L-cu-Aminoadipate, 
a classical inhibitor of glutamate uptake in rat (Balcar and John- 
ston, 1972), was eiamined as an inhibitor of the EAAT subtype 
and the measured K, values were > 1 mM. 
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Table 1. Glutamate uptake inhibition constants 
2 o- 
1 10 100 1000 10000 
lOrue PM 
B. EAATP 
C. EAATB 
20- 
1 10 100 1000 10000 
t0w1 PM 
Figure 4. Pharmacology of EAAT subtypes expressed by COS cell 
transfection. The potencies of glutamate uptake inhibitors were assessed 
in COS cells transfected with either EAATl (A), EAATZ (B), or EAAT3 
(C). Uptake of 1 PM ‘H L-glutamate was assessed in the presence of the 
indicated amount of inhibitor. Inhibitors were TBHA (solid squares), 
PDC (solid triangles), SOS (solid circles), DHK (open diamonds), and 
KA (solid diamonds). DHK and KA had no significant effect on EAAT l- 
and EAAT3-mediated uptake at concentrations 5 1 mM (data not shown). 
Each data set shown is from a single representative experiment per- 
formed in triplicate with individual determinations varying from the 
mean by ~20%. The K, values listed in Table 1 are from at least three 
independent experiments (mean f  SEM). Chemical names of the com- 
pounds abbreviated above are given in Table 1. 
Potentially selective and/or potent inhibitors were more ex- 
tensively characterized by full K, determinations. Representa- 
tive data for the effect of five uptake inhibitors (TBHA, PDC, 
SOS, DHK, and KA) on transport by each EAAT subtype are 
presented in Figure 4, and K, values are provided for these and 
other inhibitors (CA, LCSA, P-GLU, and LAPH) in Table 1. 
K, determined (in PM) 
Cornpour& EAATl EAAT2 EAAT3 
TPHA 32 + 8 19 + 6 25 + 5 
PDC 79 k 7 8*2 61 + 14 
SOS 107 + 8 1157 k 275 150 + 52 
DHK 23 mM 23 + 6 >3 mM 
KA >3 mM 59 + 18 >3 rnM 
CA 10 & 3 10 + 2 19 k 9 
LCSA 14 + 7 6+1 17 f  2 
@-Glu 297 + 118 156 f  37 307 k 48 
LA@H 369 + 70 184 f  27 133 k 34 
a TBHA, DL-threo+hydroxyaspartic acid; PDC, L-trans-pyrrolidine-2,4-d&w- 
boxylic acid; SOS, L-serine-O-sulfate; DHK, dihydrokainic acid; KA, kainic acid; 
CA, L-cysteic acid; LCSA, L-cysteine sultinic acid; @-Glu, b-glutamate; L&H, 
L-aspartate-@-hydroxymate. 
Table 1 also lists the abbreviations and full chemical names of 
these inhibitors. TpHA and PDC were potent inhibitors of each 
subtype, but PDC was more potent than T@HA on EAAT2 while 
TPHA was more potent than PDC on EAAT 1 and EAAT3. KA 
and DHK inhibited EAAT2 uptake with K, values of 59 + 18 
PM and 23 -t 6 PM, respectively, but had no significant effect 
on the activity of EAATl and EAAT3 at concentrations less 
than 1 mM. In contrast, SOS inhibited EAATl and EAAT3 with 
K, values of 107 + 8 pM and 150 f 52 PM, but was determined 
to have a K, of 1157 f 275 I.LM for inhibiting uptake by EAAT2. 
Thus, the rank order of potency for EAAT2 was (from the lowest 
K,) PDC < TpHA < DHK < KA < SOS, whereas the rank 
order of potency for EAATl and EAAT3 was TPHA < PDC 
< SOS < DHK, KA (Fig. 4, Table 1). One drug moderately 
useful for discriminating between EAATl and EAAT3 was 
LAPH, with K, values of 369 f 70 I.LM and 133 f 34 PM, 
respectively. 
Electrogenic transport of glutamate and analogs in Xenopus 
oocytes 
Superfusion of voltage-clamped oocytes expressing the human 
EAAT subtypes with L-glutamate and other substrates resulted 
in inward currents that were dose dependent, saturable, and 
required the presence of sodium in the superfusion media (Fig. 
5A). Kinetic parameters were determined by measuring the con- 
centration dependence of the uptake currents (Fig. 5B). The 
transport mediated by each EAAT subtype was characterized 
for each glutamate and aspartate stereoisomer, and for several 
uptake inhibitors (Table 2). Transport was stereospecific for 
L-glutamate but not for D- or L-aspartate, a characteristic of 
these sodium-dependent uptake systems (Kanner and Schul- 
diner, 1987). The K,,, values obtained in this assay system were 
similar to those determined by measuring the uptake of )H-L- 
glutamate and 3H-D-aSpartate in COS-7 cells expressing EAAT 
subtypes (compare Table 2, Fig. 3), although the affinity con- 
stants determined in oocytes were, in general, significantly lower 
than those measured in mammalian cells. The maximum cur- 
rent (I,,,,,) associated with the uptake of substrates was also 
compared by normalizing I,,,., values to the maximum current 
obtained with L-glutamate in the same oocyte. These Z,,,,, values 
varied for each substrate, and the I,,,,, values for a particular 
substrate varied between subtypes. Subtype-specific variations 
in I,,, values were most dramatic for D-glutamate (Table 2). 
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Glutamate uptake inhibitors such as PDC (Fig. 5A) and TOHA 
also elicited transport currents, and the K,,, values determined 
by electrophysiology were comparable to the K, values deter- 
mined by uptake competition in COS-7 cells (compare Tables 
1, 2). 
Mechanism of inhibition of EAAT2 uptake by KA and DHK 
Most inhibitors of glutamate uptake were found to evoke inward 
currents. In contrast, superfusion with KA did not evoke cur- 
rents in voltage-clamped oocytes expressing any of the EAAT 
subtypes, suggesting that this compound is not a transport sub- 
strate (Fig. 6A). Moreover, the coadministration of KA did not 
affect the uptake currents elicited by L-glutamate in oocytes 
expressing either EAAT 1 or EAAT3, in agreement with the lack 
of KA effect on 3H-glutamate uptake in transfected COS cells 
expressing these subtypes (Table 1) . However, the EAAT2 glu- 
tamate-induced uptake current in oocytes was significantly re- 
duced in the presence of KA (Fig. 6A). Similar results were 
obtained with the KA analogue DHK. To rule out the possibility 
that KA and DHK were transported by EAATZ via a nonelec- 
trogenic mechanism, radiolabeled KA uptake (at 1 MM) was 
compared to L-glutamate uptake (at 1 PM) in parallel assays of 
EAAT2-expressing and control COS-7 cells. Less than 0.1 pmol/ 
well/min of KA uptake was measured, as compared with 44.3 
pmol/well/min of specific L-glutamate uptake (n = 2). These 
data suggested that KA and DHK selectively block uptake me- 
diated by the EAAT2 subtype without serving as substrates for 
uptake. 
The mechanism of KA and DHK inhibition of EAAT2-me- 
diated glutamate uptake was examined in greater detail by study- 
ing the effect of increasing concentrations of KA and DHK on 
the kinetic parameters for the L-glutamate uptake currents. Con- 
centration-response curves to glutamate in the presence of 30 
PM, 100 PM, or 300 PM KA were fitted to the Michaelis-Menten 
expression, and the glutamate concentration-response curves 
were shifted in a parallel manner (Fig. 6B). Similar data was 
obtained with DHK, suggesting that KA and DHK are com- 
petitive antagonists of EAAT2-mediated uptake. Schild analysis 
(Fig. 6C) provided estimates of the KA and DHK equilibrium 
dissociation constants as 16.7 PM and 9.2 PM, respectively (Table 
2). 
Discussion 
Three members of a gene family that mediate high-affinity so- 
dium-dependent glutamate uptake were identified by molecular 
cloning from human motor cortex. The isolation of the EAAT 1, 
EAAT2, and EAAT3 cDNA sequences provides the means to 
express and characterize the properties of these transporters, 
which previously have been difficult to isolate functionally and 
study. The present study directly compares the sequence, dis- 
tribution, and function ofthis human glutamate transporter gene 
family to identify similarities and differences reflecting the in- 
trinsic properties of each subtype. 
The regional distributions of EAATl, EAAT2, and EAAT3 
RNAs were compared in brain and in peripheral tissues by 
Northern blot analyses. Because of their postulated role in syn- 
aptic transmission, there is considerable interest in defining the 
particular cell types and neuronal pathways in which glutamate 
transporter subtypes are expressed. The rat transporters GLASTl 
(Storck et al., 1992) and GLTl (Danbolt et al., 1992; Pines et 
al., 1992; Levy et al., 1993) were reported to be expressed by 
glia, while EAACl in brain was localized to neurons (Kanai and 
A. 
L-glu 3 
(PM) - Lo i” 
u V 
40nA r 
PDC 3 10 
(PM) - - 2 
v 
100 300 Na+-free 
100 
li 
300 Na+-free 
v-- 
B. 1 
P 
L-Glu 
a 
PDC 
I I 
0 50 100 150 200 250 300 
[substrate] pM 
Figure 5. Electrogenic uptake in oocytes expressing EAAT subtypes. 
A, Inward currents were elicited by the application of substrates to 
oocytes injected with synthetic transporter RNAs and voltage clamped 
at -60 mV. Dose-dependent and saturable responses to L-glutamate 
are shown for an oocyte expressing EAAT3. No uptake currents were 
observed when sodium was replaced with choline (Na+-free). Super- 
fusion of the same oocyte with PDC, a glutamate uptake inhibitor, 
evoked responses with properties similar to glutamate uptake currents. 
PDC, like most of the inhibitory compounds tested, is a glutamate 
transporter substrate. B, Uptake currents measured for L-glutamate and 
PDC were normalized to the maximum L-glutamate current determined 
in the same oocyte, and fitted to the Michaelis-Menten equation. The 
kinetic parameters listed in Table 2 for PDC and other substrates were 
obtained by this method. 
Hediger, 1992). Sequence similarities initially suggested that 
EAATl and GLASTl, EAAT2 and GLTl, and EAAT3 and 
EAACl could be subtype counterparts in different species. Com- 
parisons of our Northern distributions with those previously 
reported support the EAATyGLT 1 correspondence and suggest 
that EAAT2 may be expressed in glia. However, differences in 
peripheral tissue distributions make the subtype correspon- 
dences of EAAT 1 /GLAST 1 and EAAT3/EAAC 1 less likely, and 
recent work in our laboratory that suggests the existence of 
additional subtypes makes the assignment of species homologs 
uncertain. Although our Northern blot analyses do not provide 
cellular resolution, they do provide insight into several aspects 
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Table 2. Kinetic parameters of uptake in oocytes 
EAATl EAAT2 EAAT3 
Substrate Km (PM) Imax’ Km (~4 I maxa Km (PM) Inn.,” 
L-Glutamate 20 * 3 (1) 18 + 3 (1) 28 k 6 (1) 
L-Aspartate 16 + 1 0.68 + 0.01 7&l 0.89 + 0.04 24 f 2 0.95 + 0.03 
D-Glutamate 595 + 50 1.10 k 0.06 5360 k 420 0.20 k 0.04 1781 + 68 0.66 + 0.04 
D-Aspartate 23 + 2 0.43 -+ 0.00 13 I? 1 0.84 f 0.02 47 -t 8 0.82 -t 0.07 
TOHA 33 zk 3 0.55 * 0.01 10 + 1 0.33 + 0.02 37 -t 1 0.94 + 0.01 
PDC 28 f 2 0.52 k 0.05 7to 0.35 + 0.01 27 + 5 0.34 f 0.01 
KA - - 16.7* (0) - - 
DHK - - 9.2b (0) - - 
o Lax is normalized to the L-glutamate I,,,,, in the same oocyte. 
b Determined by Schild analysis; KA and DHK did not induce currents. 
of EAAT mRNA expression. Expression of EAAT 1 and EAAT3 
is not restricted to the brain, suggesting a role in nutrient uptake 
in other tissues. Moreover, the mRNA content of each EAAT 
subtype observed in different brain regions does not correlate 
well with the prevalence of glutamatergic neurons. Notably, 
EAAT subtypes were as abundant in the basal ganglia as in the 
hippocampus. Although the basal ganglia contains few gluta- 
matergic neurons, extensive glutamatergic innervation may ne- 
cessitate glial transporter functions. Alternatively, the partici- 
pation of glutamate transporters in the metabolic uptake of 
acidic amino acids is observed in most tissues, and such func- 
tions may be attributed to EAAT subtypes in the brain. As- 
signment of functional roles in metabolism and/or synaptic 
function to individual subtypes awaits the determination of cell 
type specificity by histochemical analyses with cellular resolu- 
tion. 
EAATl, EAAT2, and EAAT3 exhibit striking amino acid 
sequence similarities, and it could be that their structural di- 
versity has been sharply constrained by the functional com- 
plexity of the uptake process. The translocation of glutamate 
across the cell membrane involves the binding and movement 
of substrate, but this process is also coupled to the cotransport 
of several Na+ ions (Balcar and Johnston, 1972) and probably 
the countertransport of intracellular K+ (Kanner and Sharon, 
1978; Barbour et al., 1988) and OH- ions (Erecinska et al., 
1983; Bouvier et al., 1992). The transmembrane topology of 
this family of membrane-bound glycoproteins is currently un- 
resolved, with both 8 (Pines et al., 1992) and 10 (Kanai and 
Hediger, 1992) transmembrane regions models having been pro- 
posed previously. In comparing the sequences of the EAAT 
subtypes, we find that structural conservation is prevalent with- 
in, but not limited to, nine large hydrophobic regions (Fig. 1). 
Particularly well conserved are the sequences in the vicinity of 
the seventh and eighth hydrophobic region which includes both 
a serine-rich sequence motif and the conserved AA(I/V)FIAQ 
structural motif utilized to isolate these gene products. The ser- 
ine-rich sequence (SSSS in EAATl and EAAT3, ASSA in 
EAAT2) is similar to a sequence involved in glutamate binding 
to metabotropic glutamate receptors (CYHara et al., 1993). If 
this motif should comprise a portion of the transporter gluta- 
mate binding site, these sequence differences could be related 
to the differential sensitivities of EAATl/EAAT3 and EAAT2 
to several uptake inhibitors (see below). 
The molecular cloning of three glutamate transporter subtypes 
from a single species has enabled a direct comparison of their 
functional and pharmacological properties. Here, the functional 
properties of the human subtypes were compared in two dif- 
ferent assay systems. Measurements of the radiolabeled L-glu- 
tamate uptake mediated by each EAAT subtype in transfected 
mammalian cells yielded K,,, values that varied between 48 and 
97 PM. The ion flux that accompanies glutamate transport results 
in inward currents that were measured in voltage-clamped oo- 
cytes expressing each EAAT subtype. Km determinations by 
measurement of transport currents in oocytes were comparable 
to those determined by uptake in mammalian cells, although 
generally of higher affinity (18-28 PM). System differences might 
be attributed to differences in lipid composition, posttransla- 
tional modifications, or other factors. Similar differences are 
found in the literature when uptake by synaptosomal or other 
membrane preparations are compared with whole cell uptake. 
Thus, differences between L-glutamate K,,, values previously re- 
ported for cloned glutamate transporter subtypes may in part 
be due to the different assays used. The reported Km for radio- 
labeled glutamate uptake by GLAST 1 expressed in oocytes was 
77 PM (Storck et al., 1992) whereas GLTl was reported to have 
a K, of 10 PM for uptake in intact mammalian cells and 2 PM 
in membrane preparations (Pines et al., 1992) and EAACl 
yielded a glutamate K,,, of 12 PM as determined by oocyte elec- 
trophysiology (Kanai and Hediger, 1992). Based on the higher 
reported K,,,, it was suggested previously that GLASTl might 
function as a low-affinity reserve uptake system (Kanai et al., 
1993). The human glutamate transporters may have functional 
differences from those of other species, but our measurements 
provided little evidence for significant subtype differences in 
affinity for L-glutamate. 
A glutamate transporter pharmacology largely developed in 
rat synaptosomal preparation (Ferkany and Coyle, 1986; Fletch- 
er and Johnston, 199 1; Robinson et al., 199 1, 1993) was applied 
to the cloned EAAT subtypes. Surprisingly, we found that a-am- 
inoadipate (aAA) exhibited very low potency in inhibiting glu- 
tamate uptake by the EAAT subtypes. This result contrasts with 
findings in rat cerebellar synaptosomes where an IC,, of 20-40 
PM was determined for aAA (Robinson et al., 199 1, 1993), and 
with the previously reported sensitivity of cloned GLTl and 
EAACl to this compound (Kanai and Hediger, 1992; Pines et 
al., 1992). ODAP, quisqualate and P-p-chlorophenylglutamic 
acid are other compounds reported to inhibit transport that were 
of low potency in our assays. ODAP was reported to potently 
inhibit transport in rat and primate synaptosomes (Lakshmanan 
and Padmanaban, 1974b), and it is the excitotoxin implicated 
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Figure 6. Kainate and dihydrokainate are competitive blockers of EAATZ-mediated uptake. A, The application of KA (100 PM) did not elicit 
currents in oocytes expressing either EAATl, EAATZ, or EAAT3. However, the currents elicited by L-glutamate (100 PM) were inhibited significantly 
by the coadministration of KA in oocytes expressing EAAT2, but not EAATl or EAAT3. These data confirm that KA selectively blocks EAATZ- 
mediated glutamate uptake. B, Dose-dependent i ward currents elicited by the superfusion of EAATZ-expressing oocytes with L-glutamate (circles) 
undergo parallel shifts with the addition of 30 PM (triangles), 100 PM (diamonds), or 300 PM (squares) of KA. Moreover, KA inhibition was abolished 
at high glutamate concentrations. These data indicate that KA competitively blocks EAAT2-mediated uptake. C, The antagonist equilibrium 
dissociation constants of KA (solid diamonds) and DHK (open diamonds) were estimated from Schild plots. The agonist dose ratio (r) at each 
antagonist concentration was calculated from the data shown in B for KA, and from similar DHK data not shown. Each line was fit to the data 
by least squares and with a slope of 1, and the KA and DHK K, values given in Table 2 were obtained from the abscissa1 intercept. 
in the human degenerative disease lathyrism (Spencer et al., 
1986). These results may suggest pharmacological differences 
between the human subtypes and those of other species, but 
also indicate that other EAAT subtypes or glutamate transport 
systems exist. Regional differences in pharmacology have sug- 
gested the existence of at least four glutamate transporter sub- 
types (Robinson et al., 1993), and distinct glutamate uptake 
systems have also been described. 
The EAAT subtypes fall into two distinct groupings based on 
differences in uptake inhibitor pharmacology. EAAT2-mediated 
uptake in mammalian cells was 7-IO-fold more sensitive to 
PDC than the EAATl and EAAT3 subtypes (Table 1). The 
EAATl/EAAT3 subtypes, on the other hand, were much more 
potently inhibited by SOS than was EAAT2. Pharmacological 
distinctions between the EAAT2 and EAATl/EAAT3 subtypes, 
however, were most clearly demonstrated by KA and DHK. 
EAAT2-mediated transport in COS-7 cells was inhibited by KA 
and DHK with K, values of 23 and 59 PM, respectively, but 
these agents did not significantly affect uptake by EAATl or 
EAAT3. Compounds such as PDC were determined to be sub- 
strates because they elicited specific uptake currents in oocytes 
expressing the EAAT subtypes. KA and DHK, on the other 
hand, did not evoke currents via any. EAAT subtype, and these 
compounds were found to inhibit only the glutamate uptake 
currents mediated by EAAT2. It has been reported previously 
that KA and DHK are not transport substrates (Lakshmanan 
and Padmanaban, 1974a; Johnston et al., 1979), and that both 
compounds, but particularly DHK, inhibit glutamate uptake 
with the greatest potency in synaptosomes prepared from rat 
striatum (Robinson et al., 199 1, 1993). EAAT2 mRNA was the 
most abundant subtype transcript in human basal ganglia, and 
we identify this as a KA/DHK-sensitive subtype. 
The structure of the glutamate conformer that binds to so- 
dium-dependent glutamate transporters has been studied using 
structurally constrained glutamate analogs (Chamberlin and 
Bridges, 1993; Bridges et al., 1993). These studies utilized syn- 
aptosomal preparations likely to contain mixed subtypes, and 
the application of these structural concepts to the pharmacology 
of the cloned transporter subtypes is of interest. PDC, KA, and 
DHK are glutamate analogs that can be viewed as containing a 
similar embedded glutamate conformer, but differing by the 
addition of isopropenyl or isopropyl groups at the 4-positions 
of KA or DHK, respectively (Bridges et al., 1993; Chamberlin 
and Bridges, 1993). We found PDC to be a substrate of each 
EAAT subtype. KA/DHK did not interact with EAATl and 
EAAT3, possibly because of steric inhibition by the additional 
alkyl groups. The binding of KA/DHK to EAAT2, on the other 
hand, occurs with high affinity (equilibrium constants of 17 and 
9 PM, respectively, in oocytes), but these agents cannot undergo 
membrane translocation. Structural differences between the 
EAAT2 and EAATl/EAAT3 substrate binding sites should be 
identifiable that give rise to these distinct pharmacologies. None 
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of the compounds that we have tested thus far provide such a 
clear distinction between the properties of EAATl and EAAT3, 
and this is an additional area for further investigations. 
In addition to the activation of glutamate receptors, the in- 
teractions of excitatory amino acids and their analogs with higb- 
affinity uptake systems can be a significant determinant of their 
neurotoxicity (Choi et al., 1987; Rosenberg et al., 1992). The 
toxicity of TPHA, a high-affinity substrate for each EAAT sub- 
type, may be due in part to the inhibition of glutamate uptake 
(McBean and Roberts, 1985). KA is one of the most potent 
neurotoxins known, and its toxicity relative to glutamate is likely 
to be enhanced because it is not readily taken up (Garthwaite, 
1985). The weak inhibition of glutamate uptake described in 
rat brain synaptosomes by KA (Lakshmanan and Padmanaban, 
1974a; Robinson et al., 1993) and the potent inhibition of the 
EAAT2 subtype demonstrated here may be additional com- 
ponent in KA toxicity. Lesion studies in the rat striatum have 
shown glutamatergic innervation to be essential for KA toxicity 
(McGeer et al., 1978), and elevated glutamate levels due to KA 
inhibition of uptake could provide an essential component of 
neurotoxicity. These data suggest the importance of understand- 
ing the interactions of excitatory amino acids and their ana- 
logues with the various transport systems. The cloning and func- 
tional assays utilized here to characterize EAAT 1, EAAT2, and 
EAAT3 provide a basis for future research into the structure, 
function, and pharmacology of these transporters. 
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